Economic evaluations of HIV prevention in rich countries and the need to focus on the aging of the HIV-positive population

Current Opinion in HIV and AIDS

Volumn 5, Issue 3, 2010, Pages 255-260

  Brent, Robert J ^a   Brennan, Mark ^b   Karpiak, Stephen E ^b  

^a FORDHAM UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Economic evaluations; Elderly adults; HIV; Prevention

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FUNDING; GROUPS BY AGE; HEALTH EDUCATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; REVIEW;

AGING; AIDS SERODIAGNOSIS; ANTI-RETROVIRAL AGENTS; COMMUNICABLE DISEASE CONTROL; HEALTH SERVICES RESEARCH; HIV INFECTIONS; HUMANS; UNITED STATES;

EID: 77951090471     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283384a88     Document Type: Review

References (65)

1. Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr 2009 [Epub ahead of print].
2. Karpiak SE, Brennan M. The emerging population of older adults with HIV and introduction to the ROAH research study. In: Brennan M, Karpiak SE, Shippy RA, Cantor MH, editors. Older adults with HIV: an in-depth examination of an emerging population. Hauppauge, NY: Nova Science Publishers; 2009.
3. CDC [Center for Disease Control and Prevention] Table 10: estimated numbers of persons living with AIDS, by year and selected characteristics, 2001-2005: United States and dependent areas (Revised June 2007). 2005. Retrieved March 20, 2009 from the World Wide Web: http://www. cdc.gov/hiv/topics/surveillance/resources/reports/2005report/pdf/table10. pdf.
4. CDC [Center for Disease Control and Prevention]. AIDS cases by age. 2008. Retrieved March 20, 2009 from the World Wide Web: http://www.cdc.gov/ hiv/topics/surveillance/basic.htm#aidsage.
5. Johnson CJ, Heckman TG, Hansen NB, et al. Adherence to antiretroviral medication in older adults living with HIV/AIDS: a comparison of alternative models. AIDS Care 2009; 21:541-551.
6. Velkoff VA, Kowal PR, US Census Bureau. Current population reports, P95/ 07-1 population aging in sub-Saharan Africa: demographic dimensions 2006. U.S. Government Printing Office, Washington DC; 2007.
7. Waning B, Kaplan W, King AC, et al. Strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. Bull World Health Organ 2009; 87:520-528.
8. Badri M, Cleary S, Maartens G, et al. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther 2006; 11:63-72.
9. Simone MJ, Appelbaum J. HIV in older adults. Geriatrics 2008; 63: 6-12.
10. Applebaum AJ, Richardson MA, Brady SM, et al. Gender and other psychosocial factors as predictors of adherence to Highly Active Antiretroviral Therapy (HAART) in adults with comorbid HIV/AIDS, psychiatric and substance- related disorder. AIDS Behav 2009; 13:60-65.
11. Diiorio C, McCarty F, Depadilla L, et al. Adherence to antiretroviral medication regimens: a test of a psychosocial model. AIDS Behav 2009; 13:10-22.
12. Royal SW, Kidder DP, Patrabansh S, et al. Factors associated with adherence to highly active antiretroviral therapy in homeless or unstably housed adults living with HIV. AIDS Care 2009; 21:448-455.
13. Pence BW. The impact of mental health and traumatic life experiences on antiretroviral treatment outcomes for people living with HIV/AIDS. J Antimicrob Chemother 2009; 63:636-640.
14. Applebaum AJ, Brennan M. Mental health. In: Brennan M, Karpiak SE, Shippy RA, et al., editors. Older adults with HIV: an in-depth examination of an emerging population. Hauppauge, NY: Nova Science Publishers; 2009.
15. Applebaum AJ, Brennan M. Substance and alcohol use. In: Brennan M, Karpiak SE, Shippy RA, et al., editors. Older adults with HIV: an in-depth examination of an emerging population. Hauppauge NY: Nova Science Publishers; 2009.
16. Kauf TL, Roskell N, Shearer A, et al. predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. Value Health 2008; 11:1144-1153.
17. Amberbir A, Woldemichael K, Getachew S, et al. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health 2008; 8:265.
18. Tuller DM, Bangsberg DR, Senkungu J, et al. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study. AIDS Behav 2009 [Epub ahead of print].
19. CDC. HIV prevention in the United States: at a critical crossroads. August 2009. Available at: www.cdc.gov/nchhstp.
20. Millet GA, Flores SA, Marks G, et al. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a metaanalysis. J Am Med Assoc 2008; 300:1674-1684.
21. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Medical Care 2006; 44:990-997.
22. Pinkerton SD, Holtgrave DR. How HIV treatment advances affect the cost- effectiveness of prevention. Med Decis Making 2000; 20:89-94.
23. Pinkerton SD, Holtgrave DR, Layde PM. Incremental cost-effectiveness of two zidovudine regimens to prevent perinatal HIV transmission in the United States. Prevent Med 2000; 30:64-69.
24. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008; 22:1829-1839.
25. Paltiel D, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost- effectiveness. CID 2009; 48:806-815.
26. Pinkerton SD, Martin JN, Roland ME, et al. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS 2004; 18:2065-2073.
27. Freedberg KA, Scharfstein JA, Seage GR III, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. J Am Med Assoc 1998; 279:130-136.
28. Walensky RP, Freedberg KA, Weinstein MC, et al. Cost-effectiveness of HIV testing and treatment in the United States. CID 2007; 45:S248-S254.
29. Holtgrave DR. Costs and consequences of the US centers for disease control and prevention's recommendations for opt-out HIV testing. PLoS Med 2007; 4:1011-1018.
30. Brent RJ. Cost-benefit analysis and healthcare evaluations. Northampton Mass: Edward Elgar; 2003.
31. Rotheram-Borus MJ, Swenderman D, Chovnick G. The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Ann Rev Clin Psychol 2009; 5:143-167.
32. Gardner EG, Maravi ME, Rietmeijer C, et al. The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care. App Health Econ Health Policy 2008; 6:145-155.
33. Sendi P, Gÿnthard H, Simcok M, et al. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. PLoS ONE 2007; 2:1-7.
34. Zaric GS, Barnett PG, Brandeau. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public health 2000; 90:1100-1111.
35. Freedberg KA, Losina E, Weinstein MC, et al. The cost-effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824-831. (Pubitemid 32222162)
36. Coco A. The cost-effectiveness of expanded testing for primary HIV infection. Ann Fam Med 2002; 3:391-399.
37. Chesson HW, Greenberg JB, Hennessy M. The cost-effectiveness of the WINGS intervention: a program to prevent HIV and sexually transmitted diseases among high-risk urban women. BMC Infect Dis 2002; http:// www.biomedcentral.com/1471- 2334/2/24.
38. Schackman BR, Scott CA, Walensky RP, et al. The cost-effectiveness of HLA-B-5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008; 22:2025-2033.
39. Paltiel DA, Weinstein M, Kimmel AD, et al. Expanded screening for HIV in the United States: an analysis of cost-effectiveness. N Engl J Med 2005; 352:586-595.
40. Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, et al. Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV. AIDS 2001; 15:917-928.
41. Kaplan RM, Bush JW. Health related quality of life measurement for evaluation research and policy analysis. Health Psychol 1982; 1:61-80.
42. Hubben GAA, Bos JM, Veltman-Starkenburg CA, et al. Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in The Netherlands. Cost-Effect Resource Alloc 2007; 5:15.
43. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11-19.
44. Postma MJ, Beck EJ, Mandalia S, et al. Universal HIV screening of pregnant women in England: cost-effectiveness analysis. Br Med J 1999; 318:1656-1660.
45. Eisenstaedt RS, Getzen T. Screening blood donors for human immunodeficiency virus antibody: cost-benefit analysis. Am J Public Health 1988; 78:450-454.
46. McKay NL, Phillips KM. An economic evaluation of mandatory premarital testing for HIV. Inquiry 1991; 28:236-248.
47. Holtgrave DR, Valdiserri RO, Gerber R, et al. Human immunodeficiency virus counseling, testing, referral, and notification services: a cost-benefit analysis. Arch Intern Med 1993; 153:1225-1230.
48. La Croix SJ, Russo G. A cost-benefit analysis of voluntary routine HIV testing for hospital patients. Soc Sci Med 1996; 42:1259-1272.
49. Zowall H, Fraser RD, Gilmore N, et al. HIV antibody screening among immigrants: a cost-benefit analysis. Can Med Assoc J 1990; 143:101-107.
50. Phillips KA, Madala T, Johnson FR. Measuring preferences for healthcare intervention using conjoint analysis: an application to HIV testing. Health Services Res 2002; 37:1681-1704.
51. Brent RJ. A cost-benefit analysis of a condom social marketing program in Tanzania. Appl Econ 2009; 41:497-509.
52. Brent RJ. An implicit price of a DALY for use in a cost-benefit analysis of ARVs. Appl Econ 2009 [Epub ahead of print].
53. Brent RJ. A social cost-benefit criterion for evaluating voluntary counseling and testing with an application to Tanzania. Health Econ 2009 [Epub ahead of print].
54. Brent RJ. A cost-benefit analysis of female primary education as a means of reducing HIV-AIDS in Tanzania. Appl Econ 2009; 41:1731-1743.
55. Brent RJ. Setting priorities for HIV/AIDS: a cost-benefit approach. Northampton, Mass: Edward Elgar.2010.
56. Akers AY, Bernstein L, Doyle J, Corbie-Smith G. Older women and HIV testing: examining the relationship between HIV testing history, age, and lifetime HIV risk behaviors. Sex Transm Dis 2008; 35:420-423.
57. CDC [Center for Disease Control and Prevention]. HIV/AIDS surveillance report, 19. 2007. Retrieved December 2, 2008 from the World Wide Web: http://cdc.gov/hiv/topics/surveillance/resources/reports/2007report/pdf/ 2007SurveillanceReport.pdf.
58. CDC [Center for Disease Control and Prevention]. Morbidity and Mortality Weekly Report, September 22, 2006 /55(RR14); 1-17. 2007. Retrieved December 15, 2009 from the World Wide Web: http://www.cdc.gov/mmwr/ preview/mmwrhtml/ rr5514a1.htm.
59. CDC [Center for Disease Control and Prevention]. HIV/AIDS among persons 50 and older. 2008. Retrieved May 19, 2008 from the World Wide Web: http://www.cdc.gov/hiv/topics/over50/resources/factsheets/pdf/ over50.pdf.
60. Manfredi R, Calza L. HIV infection and AIDS in advanced age. Epidemiological and clinical issues, and therapeutic and management problems. Infez Med 2004; 12:152-173.
61. Golub SA, Grov C, Tomaselli J. Sexual behavior among HIV+ older adults. In: Brennan M, Karpiak SE, Shippy RA, Cantor MH, editors. Older adults with HIV: an in-depth examination of an emerging population. Hauppauge, NY: Nova Science Publishers; 2009.
62. Cooperman NA, Arnsten JH, Klein RS. Current sexual activity and risky sexual behavior in older men with or at risk for HIV infection. AIDS Educ Prev 2007; 19:321-333.
63. Orel NA, Wright JM, Wagner J. Scarcity of HIV/AIDS risk-reduction materials targeting the needs of older adults among state departments of public health. Gerontologist 2004; 44:693-696.
64. Orel NA, Spence M, Steele J. Getting the message out to older adults: effective HIV health education risk reduction publications. J Appl Gerontol 2005; 24:490-508.
65. Jacquescoley E. Behavioral prevention study gauges HIV/AIDS and depression in the older US population. AIDS Care 2008; 20:1152-1153.